| Withdrawn | hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation NCT06444022 | Nanfang Hospital, Southern Medical University | Phase 1 |
| Not Yet Recruiting | Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease NCT07535008 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) NCT07285889 | First Affiliated Hospital of Zhejiang University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorde NCT07188909 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT NCT07047456 | Anhui Provincial Hospital | Phase 3 |
| Not Yet Recruiting | A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell NCT06949267 | Ruijin Hospital | EARLY_Phase 1 |
| Recruiting | MAGIC Ruxolitinib for aGVHD NCT06936566 | John Levine | Phase 2 |
| Not Yet Recruiting | A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD NCT06941350 | Nuwacell Biotechnologies Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model NCT06880419 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment NCT06904599 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Recruiting | Universal CNK-UT Therapy for Refractory aGVHD NCT06750133 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Unknown | A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. NCT04971551 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 2 |
| Recruiting | Tissue-resident Immune Cell Subsets in aGVHD NCT06708507 | Nanfang Hospital, Southern Medical University | — |
| Not Yet Recruiting | A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transp NCT06593834 | Yamin Fan | N/A |
| Recruiting | A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD. NCT07070674 | Accro Bioscience (Suzhou) Limited | Phase 1 |
| Not Yet Recruiting | Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD NCT06473909 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Proph NCT06480630 | Anhui Provincial Hospital | Phase 2 |
| Not Yet Recruiting | Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI NCT06490562 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Not Yet Recruiting | Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study NCT06386445 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Recruiting | Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases NCT06294691 | Anhui Provincial Hospital | Phase 3 |
| Active Not Recruiting | Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies NCT06294678 | Anhui Provincial Hospital | Phase 3 |
| Active Not Recruiting | Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Al NCT06026371 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Donor Neutrophil Subsets to Predict the Risk of aGVHD NCT06394895 | Nanfang Hospital, Southern Medical University | — |
| Not Yet Recruiting | ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) NCT04883918 | ASC Therapeutics | Phase 2 |
| Withdrawn | Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease NCT04280471 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD NCT05921305 | Peking University People's Hospital | Phase 3 |
| Recruiting | Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem NCT05443425 | City of Hope Medical Center | Phase 1 |
| Terminated | Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids NCT05123040 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Unknown | Safety and Clinical Activity of Itolizumab in aGVHD NCT05823675 | Biotech Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Particip NCT05673876 | Genentech, Inc. | Phase 1 |
| Terminated | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus H NCT05263999 | Equillium | Phase 3 |
| Unknown | Safety and Tolerability of FMT Capsules in Healthy Volunteers NCT05352269 | Shenzhen Xbiome Biotech Co., Ltd. | Phase 1 |
| Terminated | Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD NCT04910152 | Hannah Choe, MD | Phase 1 / Phase 2 |
| Recruiting | Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial NCT05236062 | Dana-Farber Cancer Institute | N/A |
| Completed | Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT NCT05825833 | IRCCS Burlo Garofolo | — |
| Completed | Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation NCT05149365 | The First Affiliated Hospital of Soochow University | Phase 3 |
| Completed | Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease NCT05121142 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Unknown | HBOT in the Treatment and Prevention of aGVHD NCT05078073 | Shandong Provincial Hospital | N/A |
| Unknown | Abatacept s.c. for aGVHD Prevention in Haplo-HCT NCT04686929 | The First Affiliated Hospital of Soochow University | Phase 1 / Phase 2 |
| Unknown | MTX and Steroid for III-IV aGVHD Treatment NCT04958538 | Peking University People's Hospital | Phase 2 |
| Terminated | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myelo NCT04095858 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Terminated | ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant NCT04006652 | Washington University School of Medicine | Phase 1 |
| Completed | Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care i NCT04539470 | Genentech, Inc. | Phase 1 |
| Unknown | Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transpla NCT03764228 | Peking University People's Hospital | N/A |
| Active Not Recruiting | Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host NCT04291261 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Unknown | FMT for Steroid Resistant Gut Acute GVHD NCT04285424 | Affiliated Hospital to Academy of Military Medical Sciences | EARLY_Phase 1 |
| Terminated | Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disea NCT03721965 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem NCT04014790 | Regimmune Corporation | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD NCT03763318 | Equillium | Phase 1 / Phase 2 |
| Active Not Recruiting | The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in NCT03805789 | CSL Behring | Phase 2 / Phase 3 |
| Completed | Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Gra NCT03491215 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | UCMSCs as Front-line Approach of Treatment for Patients With aGVHD NCT03847844 | Cytopeutics Sdn. Bhd. | Phase 1 / Phase 2 |
| Unknown | A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First- NCT03605940 | Central Hospital, Nancy, France | Phase 2 |
| Terminated | Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies NCT03557749 | Masonic Cancer Center, University of Minnesota | — |
| Completed | Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host D NCT03158896 | University of Kansas Medical Center | Phase 1 |
| Active Not Recruiting | Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell T NCT03057054 | Children's Oncology Group | Phase 3 |
| Completed | Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Hos NCT03497273 | Incyte Corporation | Phase 1 |
| Completed | An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) NCT03339297 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | FMT in Gut aGVHD Treated NCT03148743 | The First Affiliated Hospital of Soochow University | — |
| Completed | Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections NCT02805946 | Radboud University Medical Center | Phase 4 |
| Completed | Clinical Trial With MSC for Graft Versus Host Disease Treatment NCT02687646 | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Phase 1 / Phase 2 |
| Completed | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies NCT02743351 | Fate Therapeutics | Phase 1 / Phase 2 |
| Completed | Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease NCT02133924 | John Levine | Phase 2 |
| Withdrawn | Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastroint NCT02425813 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy NCT04521777 | M.D. Anderson Cancer Center | N/A |
| Terminated | A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Tra NCT02436460 | AbGenomics B.V Taiwan Branch | Phase 1 |
| Active Not Recruiting | Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease NCT02611180 | Washington University School of Medicine | — |
| Unknown | Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease NCT02392780 | moshe yeshurun | Phase 2 |
| Unknown | Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation NCT02659657 | Peking University People's Hospital | Phase 2 |
| Completed | BMT Autologous MSCs for GvHD NCT02359929 | Emory University | Phase 1 |
| Terminated | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Ho NCT02245412 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Unknown | MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVH NCT02241018 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Unknown | Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantatio NCT02044185 | Seoul St. Mary's Hospital | — |
| Terminated | Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) NCT01903473 | University of Liege | Phase 2 |
| Unknown | Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease NCT01765634 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Unknown | PETCT for Diagnosing and Monitoring Acute GVHD NCT01596192 | Rabin Medical Center | — |
| Completed | Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease NCT01521039 | Ohio State University Comprehensive Cancer Center | — |
| Terminated | Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease NCT01475162 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Completed | Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT NCT02175615 | Lee Dupuis | — |
| Terminated | Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD) NCT01140984 | Hadassah Medical Organization | N/A |
| Withdrawn | Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease NCT00640497 | Henogen | Phase 1 / Phase 2 |
| Completed | Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantat NCT00803010 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease NCT00726375 | University of Michigan Rogel Cancer Center | Phase 3 |
| Completed | Markers of Inflammation in Hematopoietic Stem Cell Transplant NCT00579397 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Terminated | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT NCT01220297 | Stanford University | Phase 2 |
| Terminated | Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease NCT00282503 | Mallinckrodt | Phase 3 |
| Terminated | Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD NCT00032773 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD NCT00038792 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| No Longer Available | Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After NCT03172455 | Impatients N.V. trading as myTomorrows | — |